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A B S T R A C T
Background: Circulating peripheral blood mononuclear cells (PBMCs) are exposed to metabolic and
immunological stimuli that inﬂuence their functionality. We hypothesized that prevailing vitamin D status
[25(OH)D] would modulate the bioenergetic proﬁle of PBMCs derived from humans.
Materials and methods: 38 participants (16 males, 22 females) ranging in body fat from 14–51% were studied.
PBMCs were isolated from whole blood, counted and freshly seeded for bioenergetic analysis using the Seahorse
XFe96 ﬂux analyser. Whole body energy metabolism via indirect calorimetry, body composition by dual-energy
X-ray absorptiometry, and relevant clinical biochemistry were measured. Data was analysed based on 25(OH)D
cut-oﬀs of < 50 nmol/L (Group 1, n=12), 50–75 nmol/L (Group 2, n=15) and ≥75 nmol/L (Group 3, n=11). A
multivariate general linear model adjusting for age, fat mass, fat-free mass, parathyroid hormone and insulin
sensitivity was used.
Results: There were signiﬁcant diﬀerences in cellular mitochondrial function between groups. Group 1 had
signiﬁcantly higher basal respiration (p=0.001), non-mitochondrial respiration (p=0.009), ATP production
(p=0.001), proton leak (p=0.018), background glycolysis (p=0.023) and glycolytic reserve (p=0.039) relative to
either Group 2 or Group 3; the latter two did not diﬀer on any measures. There were no diﬀerences in
bioenergetic health index (BHI), resting metabolic rates and systemic inﬂammatory markers between groups.
Conclusions: Inadequate vitamin D status adversely inﬂuenced bioenergetic parameters of PBMCs obtained
from adults, in a pattern consistent with increased oxidative metabolism and activation of these cells.
1. Introduction
Insuﬃcient vitamin D status [25(OH)D] is commonly observed
worldwide. Several epidemiological studies in the United States,
Canada, United Kingdom, and New Zealand have reported a high
prevalence of inadequate levels of 25(OH)D [1]. Currently, the
importance of achieving and maintaining adequacy is limited to the
prevention of rickets, osteoporosis and fractures [2]. However, many
have argued that a causal link between 25(OH) D insuﬃciency, obesity
and other diseases may exist [2–5]. Consequently the concentration of
circulating 25(OH)D that best represents suﬃciency for extra-skeletal
health, is currently debated. While some research groups argue that
50 nmol/L [6,7] is suﬃcient, others have proposed that the value
should be raised to 75 nmol/L [8,9].
Cellular and animal models strongly argue for a role of vitamin D in
immune function and energy metabolism. The vitamin D receptor
(VDR), through which the majority of eﬀects dependent on vitamin D
are exerted, is found in most cells of the immune system, including
activated lymphocytes, dendritic cells and macrophages [10]. The
active metabolite, 1,25(OH)2D, is a well-known regulator of immune
function and in a recent systematic review we showcased that the active
metabolite was strongly associated with an anti-inﬂammatory cytokine
proﬁle in peripheral blood mononuclear cells (PBMCs) [11].
1,25(OH)2D also enhanced the antimicrobial actions of macrophages,
and promoted chemotaxis and phagocytic capabilities of innate im-
mune cells [12]. The eﬀect of 25(OH)D on cytokine release from
immune cells is under-researched. One study has suggested that
25(OH)D had an anti-inﬂammatory eﬀect as gauged from an increased
IL-10 release with decreased concentrations of TNF-α levels [13], IL-6
and TNF-α mRNA, while another has observed a mixed proﬁle [14].
The VDR has been identiﬁed in all key organs of energy metabolism
including the pancreas, adipose, liver and skeletal muscle [15]. Low
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25(OH)D, and the absence of vitamin D function in VDR knockout
mice, resulted in an increase in energy expenditure [19,20]. Prevailing
25(OH)D levels are crucial since they inﬂuence local tissue concentra-
tions of the active metabolite [16]. Hence inadequate 25(OH)D may
indirectly aﬀect whole body energetics through promoting activation of
the immune system, which typically increases resting metabolic rate by
30–50% [17].
As PBMCs circulate in the vasculature, they are exposed to various
metabolic and immunological stimuli such as glucose, amino acids, free
fatty acids and vitamins. There is growing evidence that circulating
factors can mediate bioenergetic function of PBMCs [18]. Numerous
studies have harnessed PBMC's as a potential tool to determine the
inﬂammatory and metabolic status in a variety of diﬀerent disease
states, including sepsis [19], neurodegeneration [20], rheumatic dis-
ease [21], obesity [22,23], cardiovascular disease [24], diabetes melli-
tus [25,26], and anorexia nervosa [27], all of which have been linked to
mitochondrial dysfunction or altered bioenergetics. These studies in
immune cells are consistent with a large body of work suggesting
altered mitochondrial respiratory capacity and function in tissues
classically studied such as skeletal muscle, liver, islet cells, and the
myocardium [28–31]. Recently, the concept of a bioenergetic health
index (BHI) has been proposed as a novel prognostic or diagnostic
biomarker of disease [32].
The aim of the current study was to determine whether prevailing
25(OH)D inﬂuenced the bioenergetics of circulating leukocytes. To the
best of our knowledge, the impact of the prevailing 25(OH)D status on
bioenergetics and the BHI has not been previously described. A
secondary objective was to determine whether PBMC bioenergetic
parameters were associated with whole body energy metabolism in the
same person. We have presented our hypothesis through a schematic
that links low vitamin D status to a decreased BHI (Fig. 1).
Intermediates in this pathway are higher levels of inﬂammation and
greater insulin resistance (lesser insulin sensitivity) that indepen-
dently, or in combination, would aﬀect BHI. Since a heightened
inﬂammatory status is energetically expensive, we have also proposed
a link to whole body resting metabolic rate (RMR) and whole body fuel
oxidation, i.e. respiratory quotient (RQ). Finally, we have included the
possibility that a lower BHI per se could increase the demand and
utilisation of vitamin D in order to restore cell functioning, and hence
act as a driver of the low vitamin status in a feed forward loop (Fig. 1).
2. Materials and methods
2.1. Participant recruitment
Participants were recruited via ﬂyer advertisement, radio adver-
tisement, community newspapers and social media websites.
Interested participants were assessed for eligibility through a short
screening questionnaire. Inclusion criteria were as follows: Australians
of European origin; aged between 20 and 70 years; body mass index
(BMI) ≥18.5 kg/m2, weight stable ( ± 3 kg over the last six months);
not suﬀering from any medical conditions involving the thyroid, liver,
kidney or heart; absence of pregnancy; no history of cigarette smoking
within a year prior to the study; not suﬀering from any current illness
or infection requiring antibiotics; no gastrointestinal problems or
history of gastrointestinal surgeries; no history of blood disorders; no
history of mitochondrial disease; not on any medications that inﬂuence
mitochondrial function (insulin, HMG-CoA reductase inhibitors, thia-
zolidinedione's), not on anti-convulsants (increased catabolism of
vitamin D), not taking the following: parathyroid hormone (PTH) or
its derivatives, calcitonin, HRT, corticosteroids, vitamin D supplements
or any special or commercial diet programs that may aﬀect the body's
metabolism. This study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures involving
human volunteers were approved by the Human Research Ethics
Committee of Curtin University, Perth, Western Australia (Ethics
approval number RDHS-13-15). Written informed consent was ob-
tained from all participants.
2.2. Intervention
Participants arrived at the laboratory after an overnight fast of 10–
12 h, after refraining from strenuous physical activity 24 h prior to, and
on the morning before the study day.
2.2.1. Physical characteristics and body composition
Weight was measured using an electronic platform balance (CW-11,
Precision Balances Pty Ltd). Height was measured using a stadiometer
ﬁxed to a wall (Seca, Hamburg, Germany). Waist circumference was
measured at the umbilicus. Body composition including fat mass (FM)
and fat free mass (FFM) was assessed by dual energy x-ray absorptio-
metry (Prodigy, Lunar Corp USA).
2.2.2. Resting metabolic rate
Resting metabolic rate (RMR) was measured in the environmental
chamber housed at the School of Public Health, Curtin University,
Western Australia. The chamber is a purpose built structure within a
large room of the building. It has a volume of 57.75 m3, insulated walls
and roof and is independently controlled for temperature range from
4 °C to 50 °C. Participants ﬁrst rested in the supine position for 30 min
to equilibrate with the temperature of the environmental chamber that
was set at 25 °C the day before. A trial RMR measurement was made to
accustom participants to the canopy of the TrueOne indirect calori-
metry system (Parvo Medics, USA). RMR was then measured for
30 min, with the ﬁrst 10 min excluded from the calculations. RMR in
kJ/d was derived from CO2 production and O2 consumption according
Fig. 1. Vitamin D status, inﬂammation and bioenergetic health. Legend: Inadequate
vitamin D status promotes an inﬂammatory state. Together they reduce whole body
insulin sensitivity and the bioenergetics of peripheral blood mononuclear cells. The
resultant lower BHI, an indicator of mitochondrial health status, will possibly drive an
increase in whole body resting metabolism (RMR). A heightened inﬂammatory state is
also energetically expensive and account for a greater whole body energy requirement,
while a lower insulin sensitivity will increase RMR and decrease respiratory quotient
(RQ). Finally a low BHI per se has the potential to increase the demand for vitamin D in
an attempt to maintain cellular function, hence leading to a further lowering of vitamin D
status. Improvement of vitamin D status (increased sun exposure or supplementation)
will act to reverse this dysmetabolism through lesser inﬂammation and greater BHI. ↑,
increased; ↓, decreased; red arrows indicate pathways tested in this paper and blue
arrows indicate what is known. BHI, bioenergetic health index; RMR, resting metabolic
rate. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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to the Weir's formula, neglecting protein oxidation in the fasting state.
Fasting respiratory quotient was calculated as volume of CO2 pro-
duced/volume O2 consumed. The TrueOne system was calibrated with
gas mixtures of known composition before each measurement session
and performance of the system was regularly checked through 30 min
ethanol burn tests. A mean ± SD for six tests gave an RQ of 0.67 ± 0.01.
2.2.3. Blood collection and analysis
A fasting venous sample was obtained after 90 min exposure to the
set temperature by experienced phlebotomists. Brieﬂy, fasting blood
glucose were determined using routine automated procedures on an
Architect c16000 analyser that used speciﬁc enzyme-based colorimetric
reagents (Abbott Diagnostics; CV < 2%). Fasting insulin was deter-
mined by PathWest Laboratories Perth Australia using an Architect
i2000SR Analyser (Abbott Diagnostics; CV < 3%). PTH was determined
using a Cobas e601 Analyser (Roche Diagnostics). Quantitative insulin
sensitivity check index (QUICKI) was determined from fasting glucose
and insulin [33]. 25(OH)D was measured by chemiluminescent micro
particle immunoassay (Architect 25-OH Vitamin D assay, Abbott
Diagnostics). Inﬂammatory cytokines IL-6, IL-8, IL-10, IL-12p70 and
TNF-α were measured using Human High Sensitivity T Cell kits and
run on a MAGPIX® system (Merck Millipore, Germany). All samples
were measured in duplicate, and the average of the two values was used
for data analyses. CRP was measured using QuickRead go CRP kits
from Orian Diagnostica (Espoo, Finland).
2.2.4. Immune cell isolation and population determination
Eighteen millilitres of whole blood was drawn by venepuncture into
commercially available EDTA-citrate vacutainers, from patients fasting
overnight and diluted 1:1 in PBS-EDTA (2 mM). The diluted blood was
transferred to a fresh tube containing an equivalent volume of
Histopaque 1077 (Sigma-Aldrich, St Louis, USA) and centrifuged at
600×g for 20 min with minimum acceleration and no braking.
Autologous plasma samples (3mls) were taken from the upper layer,
while immune cells were isolated from the “buﬀy coat” and washed
with EDTA-free PBS. Washing and centrifugation was repeated at 300,
200 and 100 g for 10 min each, to remove contaminating platelets. The
cell pellet was re-suspended in 0.5 ml of warm RPMI-1640 (10% FBS,
2 mM glutamine, 100 U/ml penicillin & 0.1 mg/ml streptomycin), and
an aliquot taken to determine the cell number and percentage propor-
tion of immune cells (lymphocytes, monocytes and granulocytes) using
the automatic Mindray BC2800 haematological analyser. The cell
suspension was seeded into the Seahorse assay XFe96 culture plate.
All samples were processed within 5 h of blood collection.
2.2.5. Seahorse XFe96 measurements
As per our previously established protocol [34], cells were seeded at
a density of 3.5×105 cells/well into 96 well plates previously coated
with poly-D-lysine (50 μg/mL) to maximise adherence and allowed to
adhere overnight. After recording of basal measurements, the Mito
Stress Test injection strategy consisted of oligomycin (5 µM), FCCP
(1.5 µM), and rotenone/antimycin A in combination (5 µM). The
Glycolytic Stress Test injection strategy consisted of glucose (25 mM),
oligomycin (5 µM), followed by 200 mM 2-deoxyglucose (2DG).
Oxygen consumption rate (OCR) and proton production rate (PPR)
was measured using ﬁve 2 min cycles of mix and measurement
following each injection.
2.2.6. Seahorse data analysis
Basal respiration was calculated by subtracting the minimum OCR
following addition of rotenone/antimycin A (non-mitochondrial re-
spiration) from the last OCR measurement recorded prior to addition
of oligomycin. Proton leak was calculated by subtracting the minimum
OCR following addition of rotenone/antimycin A (non-mitochondrial
respiration) from the minimum OCR measurement recorded after
addition of oligomycin. OCR related to ATP production (turnover)
was calculated by the diﬀerence between the proton leak and basal
respiration. Coupling eﬃciency percentage was calculated by dividing
the ATP production dependent OCR by the basal respiration and
multiplying by 100. Maximal respiration was determined by subtract-
ing the non-mitochondrial respiration OCR from the maximum OCR in
response to FCCP, while reserve capacity was the diﬀerence between
the basal respiration and the calculated maximal respiration. Basal
glycolysis in the presence of 0 mM glucose was determined by the last
PPR measurement recorded prior to addition of 25 mM glucose.
Glycolytic response to 25 mM glucose was determined by subtracting
the maximum PPR following addition of glucose from the last PPR
measurement prior to addition of glucose. Glycolytic capacity was
measured by subtracting the minimum PPR following 2DG addition
from the maximum PPR after injection of oligomycin. Finally,
Glycolytic reserve was determined from the diﬀerence between the
glycolytic capacity and the glycolytic response to 25 mM glucose. Each
treatment was measured in at least triplicate wells.
2.2.7. Calculation of Bioenergetic Health Index (BHI)
The BHI of each sample was calculated as previously deﬁned
[35,36] and is presented below. No power function was applied to
these parameters [35].
Bioenergetic Health Index = [Reserve Capacity × ATPproduction]
÷ [Non−mitochondrial respiration ×
Proton Leak] (34)
2.3. Statistical analysis
We categorized our study sample into three groups based on cut oﬀs
for 25(OH)D of 50 nmol/L and 75 nmol/L. Participants with 25(OH)D
< 50 nmol/L formed Group 1, 50–75 nmol/L were Group 2 and those
with status ≥75 nmol/L were deﬁned as Group 3. Normally distributed
data are presented as mean (SD) and skewed data are presented as
median (IQR). Skewed data were transformed and statistical analyses
comparing the three independent groups were performed using multi-
variate GLM. Multivariate regression was used to adjust for eﬀects of
age, fat mass (kg), fat-free mass (kg), PTH (pmol/L), and QUICKI
(quantitative insulin sensitivity check index) on all bioenergetics
parameters. These covariates were selected by a parsimonious back-
ward approach that tested for many potential variables. Pearson's
partial correlation coeﬃcients were used to determine correlations for
BHI, RQ and RMR with inﬂammatory cytokines and QUICKI. All
statistical calculations were performed using SPSS version 22 and
graphics were generated using GraphPad Prism software v. 6.0.
3. Results
3.1. Demographics, body composition and inﬂammatory proﬁle of
participants
The participant cohort consisted of 16 males and 22 females,
ranging in percent body fat from 14–51% and aged between 19 and
69 years. There were no diﬀerences between groups in gender
distribution (M/F) (Group 1: 7/5, Group 2: 5/10, Group 3: 4/7,
p=0.420), age [Group 1: 43.25 (16.65) years, Group 2: 42.00 (20.09)
years, Group 3: 40.18 (18.78) years, p=0.925] and BMI [Group 1:
26.32 (3.77) kg/m2, Group 2: 26.68 (4.04) kg/m2, Group 3: 23.6418
(3.39) kg/m2, p=0.115]. Further details of their body composition are
provided in Table 1. We did not detect diﬀerences in CRP (p=0.174),
TNF-α (p=0.952), IL-6 (p=0.883), IL-8 (p=0.986), IL-10 (p=0.499), or
IL-12p70 (p=0.09) between the three groups whether unadjusted or
adjusted for age, FM, FFM, PTH and QUICKI. Percentage of lympho-
cytes (p=0.217) and monocytes (p=0.424) also did not diﬀer between
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vitamin D status groups.
Thirty one participants had no contamination by platelets in their
samples. Seven individuals showed marginal contamination ranging
from 1000 platelets/µL to 8000 platelets/µL. Based on the total volume
aliquoted into each well, the sample with the highest contamination
would have had ~1.22 million platelets/well. The latter value is 1/20th
the number of cells needed to detect a change in oxygen consumption
of platelets [32].
3.2. Bioenergetic parameters
Insulin sensitivity was marginally diﬀerent between vitamin D
status groups, while RMR and RQ were similar among groups
(Table 1). The Mito Stress Test trace and Glycolysis Stress Test
bioenergetics responses are shown in Figs. 2 and 3, respectively. The
unadjusted bioenergetic proﬁle indicated signiﬁcant group diﬀerences
in basal respiration and ATP production. Basal respiration and ATP
production were highest in the lowest vitamin D group (Group 1; <
50 nmol/L) with trends towards a greater non-mitochondrial respira-
tion, and coupling eﬃciency (Table 1). After adjustment for age, FM,
FFM, PTH and QUICKI, group diﬀerences were accentuated for basal
respiration, non-mitochondrial respiration, ATP production, and pro-
ton leak (Table 2) with Group 1 having the highest values compared to
the other two groups. Glycolytic stress test parameters also indicated a
greater background glycolysis and glycolytic capacity (Table 2), with a
trend for higher glycolytic reserve as well. There were no diﬀerences in
adjusted parameters between Group 2 and Group 3 (Table 2). Analysis
of the data without the 7 individuals where contamination by platelets
was detected, is presented in Table S1. Those outcomes were similar in
direction and statistical signiﬁcance to outcomes of the complete
dataset in Table 2.
3.3. Correlations between bioenergetics and whole body
measurements
After adjustment for age, FM, FFM and PTH, BHI was positively
related to QUICKI (r=0.527, p=0.002) and demonstrated inverse
trends with RMR (r=−0.335, p=0.061), IL-6 (r=−0.312, p=0.082)
and TNF-α (r=−0.325, p=0.07). A similar analysis demonstrated
RMR to be positively associated with TNF-α (r=0.396, p=0.025), while
RQ was inversely correlated with QUICKI (r=−0.433, p=0.013) and
CRP (r=−0.477, p=0.006). QUICKI demonstrated a trend whereby
values were inversely correlated with MCP-1 (r=−0.305, p=0.09). Upon
Table 1
Body composition, whole body energy metabolism and bioenergetic profiles of
participants, according to vitamin D status group†.
Characteristic Whole
group
(n=38)
<
50 nmol/
L (n=12)
50–
75 nmol/L
(n=15)
≥75 nmol/
L (n=11)
P value
Body composition & whole body energy metabolism
Fat mass (kg) 22.15
(12.84)
26.41
(19.89)
25.56
(16.07)
19.69
(5.01)
0.113
Fat free mass
(kg)
52.14
(11.76)
54.93
(10.97)
51.67
(12.74)
49.75
(11.66)
0.574
PTH (pmol/L) 3.04
(1.38)
4.27
(2.52)a
2.8
(0.84)b,c
3.04 (0.86)c 0.065
QUICKI 0.37
(0.04)
0.37
(0.04)
0.37
(0.04)a
0.39 (0.02)b 0.078
RMR (kJ/d) 6136
(1415)
6535
(1444)
6333
(1513)
5433
(1058)
0.138
RQ 0.83
(0.03)
0.82
(0.04)
0.84
(0.03)
0.84 (0.03) 0.260
Mito stress test parameters
Basal
respiration
(pmol O2/min)
53.88
(21.84)
69.59
(22.22)a
43.69
(13.85)b,c
50.64
(22.13)c
0.005
Non
mitochondrial
respiration
(pmol O2/
min)#
3.5667
(0.32)
3.7389
(0.33)
3.4729
(0.23)
3.507
(0.37)
0.074
ATP production
(pmol O2/
min)#
6.16
(1.52)
7.27
(1.37)a
5.52
(1.05)b,c
5.82 (1.67)c 0.005
Proton leak
(pmol O2/min)
15.06
(4.58)
16.78
(5.04)
13.75
(4.67)
14.96
(3.62)
0.239
Maximal
respiration
(pmol O2/min)
207.89
(106.95)
240.57
(106.58)
183.98
(76.31)
204.84
(139.74)
0.402
Coupling
eﬃciency (%)
72.46
(7.20)
76.37
(6.05)a
69.68
(7.42)b
71.93
(6.57)
0.050
Reserve
capacity (pmol
O2/min)
157.03
(88.54)
178.08
(83.67)
140.91
(72.66)
156.05
(113.98)
0.568
BHI# 2.29
(0.70)
2.45
(0.68)
2.14
(0.72)
2.31 (0.73) 0.534
Glycolysis stress test parameters
Background
glycolysis
(pmol H+/
min)#
4.52
(1.05)
5.03
(0.92)
4.27
(1.03)
4.30 (1.10) 0.127
25 mM Glucose
response
(pmol H+/
min)#
0.03
(0.01)
0.03
(0.01)
0.04
(0.01)
0.04 (0.01) 0.321
Glycolytic
reserve (pmol
H+/min)#
5.49
(1.40)
6.03
(1.38)
5.27
(1.40)
5.16 (1.36) 0.257
Glycolytic
capacity (pmol
H+/min)#
7.83
(1.51)
8.55
(1.38)
7.64
(1.73)
7.29 (1.09) 0.110
Values not sharing the same superscript are significantly different from each other.
ATP, adenosine triphosphate; BHI, Bioenergetic Health Index; RMR, resting metabolic
rate; RQ, respiratory quotient; QUICKI, quantitative insulin sensitivity check index.
† Data are mean (SD) following unadjusted multivariate ANOVA.
# Variables were transformed.
Fig. 2. Eﬀect of vitamin D status on oxygen consumption rate during the Mito Stress
Test. Legend: 25(OH)D, 25-hydroxy vitamin D; OCR, oxygen consumption rate.
Fig. 3. Eﬀect of vitamin D status on proton production rate during the glycolysis stress
test. Legend: 25(OH)D, 25-hydroxy vitamin D; PPR, proton production rate.
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further adjustment for QUICKI, all associations with BHI disappeared,
however RMR remained directly related to TNF-α levels (r=0.375,
p=0.038), while RQ was inversely related to CRP (r=−0.40, p=0.024).
4. Discussion
Bioenergetic dysfunction has been demonstrated in various disease
states including Alzheimer's disease [37], type 2 diabetes [38] and
anorexia nervosa [39]. Each of these disorders has also been associated
with low vitamin D status [40–42]. There are few studies investigating
the impact of vitamin D status on energetic parameters of PBMCs, and
whether prevailing 25(OH)D, whole body energy metabolism, inﬂam-
matory markers and cellular energetics are interrelated in the same
individual was, up to now, unknown.
4.1. Main ﬁndings
Our results suggest that in vivo circulating 25(OH)D, a proxy for
vitamin D status, was associated with ex-vivo PBMC cell bioenergetics
resulting in signiﬁcantly greater basal respiration, ATP production,
proton leak, and non-mitochondrial respiration in those with 25(OH)D
< 50 nmol/L (Table 2). Concomitantly, we also uncovered signiﬁcantly
greater background glycolysis and glycolytic capacity in the same
vitamin D inadequate group (Table 2). These outcomes were consistent
whether we used the entire dataset or restricted our analysis to those
with no platelet contamination (Table S1). Overall, a lower 25(OH)D
was associated with heightened PBMC bioenergetics, both oxidative
phosphorylation and glycolysis. It appears from our data that this eﬀect
may plateau above 50 nmol/L, since the group > 75 nmol/L showed no
further change in these bioenergetic parameters (Tables 2 and S1).
To the best of our knowledge, this is the ﬁrst study to suggest there
may be an eﬀect of circulating 25(OH)D on PBMC bioenergetics. Other
studies have investigated the eﬀect of cholecalciferol ± calcium on
skeletal muscle bioenergetics using P Magnetic resonance spectroscopy
[43–45]. No overt abnormalities of skeletal muscle mitochondrial
oxidative function in vitamin D-deﬁcient subjects compared with
healthy controls were found [43], which are in contrast to the present
ﬁndings. Reasons for the discrepancy may include the diﬀerent tissues/
cells studied, and the use of small sample sizes that may not overcome
the biological variability in measurement of mitochondrial function.
Previous animal and cellular studies suggested that vitamin D
modulated energy metabolism. Mouse models demonstrate that vita-
min D deﬁciency or impaired VDR signalling (through VDR knockout),
results in increased energy expenditure. In global VDR null mice,
increased energy expenditure measured by indirect calorimetry is seen
[46]. These VDR null mice fed a high-fat diet displayed reduced lipid
accumulation in the liver through greater fatty acid oxidation and
increased expression of uncoupling proteins (UCPs), UCP-1, UCP-2,
which increases energy expenditure [46]. Dietary induced vitamin D
deﬁciency also alleviates hepatic lipid accumulation, upregulates key
enzymes involved in fatty acid oxidation and uncoupling protein 3
(UCP-3) [47]. UCP-1 is an important regulator of proton ﬂux, and can
allow dissipation of the proton gradient across the mitochondrial inner
membrane in specialised tissues such as brown adipose tissue [46].
While UCP-2 and UCP-3, will transport protons and increase the net
proton conductance of mitochondria in the presence of speciﬁc
activators. Such observations would support our ﬁndings of increased
proton leak and ATP production with low 25(OH)D, which may reﬂect
increased energy demand, increased energy expenditure, and/or
dysfunctional energy utilisation. Interestingly, recent molecular studies
have shown that the silencing of VDR signalling and impairment of
VDR translocation to the mitochondria in cancer cells, promoted
elevated mitochondrial respiration and electron transport chain activ-
ity through upregulation of cytochrome oxidase enzymes (COX II and
IV) [48]. In another study, treatment with 1,25(OH)2D reduced
glycolytic and citric acid cycle metabolic ﬂux by decreasing the
concentration of key intermediates [49]. Collectively, these cellular
studies demonstrate that VDR signalling is a regulator of glycolytic and
oxidative metabolism, and appears to function by restraining metabolic
ﬂux under normal physiological conditions.
The increased bioenergetic proﬁle associated with 25(OH)D <
50 nmol/L is consistent with enhanced oxidative stress and activation
of PBMCs. Others have previously demonstrated that oxidative stress
increases ATP-linked oxygen consumption and proton leak [50].
Chacko et al. hypothesized that oxidative stress induces increased
non-mitochondrial respiration (e.g. ROS generation), which leads to
increased proton leak and greater ATP demand; together this is
reﬂected by an increased basal respiration [35]. In leukocytes, non-
mitochondrial respiration is attributed to enzymes associated with
inﬂammation, such as cyclooxygenases, lipoxygenases and NADPH
oxidases and possibly intra-mitochondrial sources of ROS [35,36]. It is
well-recognized that activation of leukocytes increases metabolic rate;
with the increase depending on the condition that activates the
immune system. RMR was positively associated with TNF-α, after
accounting for several confounders including insulin sensitivity, while
RQ was inversely related to CRP. Such observations mimic the
increased energetic cost of an activated immune system [51].
However, immune cell fuel utilisation during low grade inﬂammation
is an area which requires further investigation as no consensus exists
regarding fuel choice by immune cells and the impact of circulating
hormones and cytokines associated with stress responses.
We found that BHI, a proposed indicator of mitochondrial health
status [32], was directly related to insulin sensitivity but inversely to
Table 2
Adjusted bioenergetic measurements compared across three groups varying in vitamin D
status†.
Characteristic < 50 nmol/L
(n=12)
50–75 nmol/
L (n=15)
> 75 nmol/L
(n=11)
P value
Whole body energy metabolism
RMR (kJ/d) 6251 (785) 6294 (766) 5796 (755) 0.236
RQ 0.82 (0.03)a 0.84 (0.04) 0.85 (0.03)b 0.100
Mito stress test parameters
Basal respiration
(pmol O2/min)
75.14
(19.94)a
40.74
(19.46)b,c
48.61
(19.18)c
0.001
Non mitochondrial
respiration (pmol
O2/min)
#
3.84 (0.33)a 3.41 (0.32)b,c 3.48 (0.32)c 0.009
ATP production (pmol
O2/min)
#
7.59 (1.4)a 5.35 (1.37)b,c 5.70 (1.35)c 0.001
Proton leak (pmol O2/
min)
18.23
(4.61)a
12.56 (4.49)b 15.00 (4.43) 0.018
Maximal respiration
(pmol O2/min)
248.83
(109.58)
189.15
(106.94)
188.77
(105.43)
0.337
Coupling eﬃciency
(%)
76.23 (7.76) 70.17(7.55) 71.36 (7.49) 0.156
Reserve capacity
(pmol O2/min)
182.78
(90.55)
146.81
(88.37)
142.87
(87.12)
0.522
BHI# 2.39 (0.69) 2.25 (0.67) 2.23 (0.66) 0.839
Glycolysis stress test parameters
Background glycolysis
(pmol H+/min)#
5.27 (1.04)a 4.07 (1.01)b,c 4.31 (0.99)c 0.023
25 mM Glucose
response (pmol H+/
min)#
0.03 (0.01) 0.04 (0.01) 0.04 (0.01) 0.253
Glycolytic reserve
(pmol H+/min)#
6.31 (1.39) 5.14 (1.46) 5.03 (1.43) 0.094
Glycolytic capacity
(pmol H+/min)#
8.79 (1.45)a 7.44 (1.43)b,c 7.30 (1.39)c 0.039
Values not sharing the same superscript are significantly different from each other.
ATP, adenosine triphosphate; BHI, Bioenergetic Health Index; RMR, resting metabolic
rate; RQ, respiratory quotient; QUICKI, quantitative insulin sensitivity check index.
† Data are mean (SD) following multivariate ANCOVA with adjustment for fat mass
(kg), fat-free mass (kg), PTH (pmol/L), and QUICKI.
# Transformed variables.
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RMR, and some markers of systemic inﬂammation. This potentially
validates a scenario where attenuation of systemic inﬂammation,
improved insulin sensitivity, reduced whole body energetic demand
and BHI are inter-linked (Fig. 1). Given that proton leak is accountable
for ~25% of RMR [52] and proton leak is associated with ineﬃcient
ETC activity, this would further enhance the conceptual arguments
presented. That these relationships were not obvious once the data
were adjusted for QUICKI, could indicate the primacy of whole body
insulin sensitivity in the derangement of bioenergetics associated with
a poor vitamin D status.
Vitamin D is recognized as an anti-inﬂammatory agent [11], thus
vitamin D may inﬂuence bioenergetics through inﬂammatory mechan-
isms. However, our study did not ﬁnd any group diﬀerences in
circulating inﬂammatory markers. Many randomized controlled trials
report no diﬀerence in inﬂammatory markers following vitamin D
supplementation [53–56], however cellular studies convincingly de-
monstrate an anti-inﬂammatory beneﬁt following exposure to
1,25(OH)2D(11). Although the majority of cellular studies have tested
the eﬀects of 1, 25(OH)2D, there is close relationship between
circulating 25(OH)D and its active metabolite. This is especially crucial
for tissues that can convert 25OHD to 1,25(OH)2D such as the immune
cells [16]. In support of this, observations that the concentration of
serum vitamin D inﬂuences cytokine secretion from peripheral blood
mononuclear immune cells has been reported [57]. We acknowledge
that measuring systemic cytokine concentrations does not provide
information on cytokine release at the local tissue level [58]. It is also
likely that we could not detect group diﬀerences between study groups
because we excluded participants with acute inﬂammatory conditions.
We also observed that insulin sensitivity tended to be highest in
Group 3 (≥75 nmol/L) (Table 1). This positive association between
vitamin D status and insulin sensitivity has been found in many cross-
sectional studies [59–61]. Furthermore in this study QUICKI trended
towards an inverse association with MCP-1, and MCP-1 has been
repeatedly demonstrated to induce insulin resistance in obese mice
models [62,63]. It is well-accepted that the insulin resistance that
accompanies obesity is attributable, at least in part, to changes in the
secretion of adipokines [64]. Overall, as the links between BHI,
inﬂammatory markers and whole body energy expenditure disappeared
on adjustment for QUICKI, insulin sensitivity may also be key to the
relationship of bioenergetics and systemic inﬂammation.
4.2. Study limitations, strengths and future directions
As a cross-sectional design we cannot conﬁrm a causal eﬀect of
25(OH)D on PBMC bioenergetics but the results strongly support the
examination of correcting inadequate vitamin D status on bioenergetics
parameters. The samples used contained a heterogeneous population
of immune cells, each of which have unique bioenergetic proﬁles, as
eloquently discussed by Chacko et al. [32] and Kramer et al. [65]. Since
immune cells in vivo interact with one another, it is likely that the
metabolic state of the whole human system is better reﬂected through a
heterogeneous sample, rather than just one immune cell type. We do
however acknowledge the value in determining the inﬂuence of vitamin
D on bioenergetic parameters in isolated and puriﬁed populations of
immune cells. Future studies may investigate whether this explains the
relationship between vitamin D status and bioenergetics that we have
observed. Despite ﬁnding signiﬁcantly increased ATP production and
non-signiﬁcant increased reserve capacity [numerator terms of the BHI
equation], we also uncovered an increased proton leak and non-
mitochondrial respiration [denominator terms]. It would appear such
eﬀects approximately cancelled out as we found no signiﬁcant diﬀer-
ences between vitamin D groups in BHI. While BHI was 7% marginally
higher in those with < 50 nmol/L compared to those with status >
75 nmol/L, our study was not powered to detect such a diﬀerence. It is
also possible that the BHI equation as originally proposed may need
modiﬁcation, however developing such an equation was outside the
scope of this manuscript given its cross sectional design.
The major strength of our study is its holistic approach that
combined metabolic proﬁling of PBMCs, whole body energy metabo-
lism parameters, markers of whole body insulin sensitivity, body
composition and systemic inﬂammatory proﬁle. This allowed a broad
overview of bioenergetics across the range of prevailing 25(OH)D seen
in this study. We believe such studies are better equipped to allow
translation of key cellular and molecular events to a clinical scenario of
disease. However they necessarily have to overcome the complexity and
inherent larger biological variability associated with the whole systems
approach, relative to isolated cell systems. There is a requirement for
well-designed randomized controlled trials to extend such ﬁndings
towards a causal role for the vitamin in human energy metabolism and
bioenergetics of leukocytes in chronic disease states.
In conclusion, this study documents for the ﬁrst time the potential
inﬂuence of vitamin D status on bioenergetics in freshly isolated
peripheral blood mononuclear cells. Taken together, these data in-
dicate a relationship between Vitamin D and immune cell bioenergetic
responses. Speciﬁcally we propose that low vitamin D status engenders
a pattern consistent with increased oxidative metabolism and inﬂam-
matory activation that is reﬂected in altered bioenergetics of PBMCs.
Future studies need to validate whether vitamin D has a causal role in
cellular function and bioenergetic health.
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